Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AqT STING agonist payload
- Development stage
- Preclinical
- Lead developer
- AqT Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AqT Therapeutics is developing a proprietary small-molecule STING (Stimulator of Interferon Genes) agonist specifically designed to serve as a payload for Antibody-Drug Conjugates (ADCs). STING is a transmembrane protein that plays a critical role in the innate immune system by sensing cytosolic DNA and triggering the production of Type I interferons and pro-inflammatory cytokines. By conjugating these agonists to tumor-targeting antibodies, AqT aims to achieve localized activation of the STING pathway within the tumor microenvironment, thereby stimulating a potent anti-tumor immune response while minimizing the systemic inflammatory side effects typically associated with non-targeted STING agonists. This asset is currently positioned for evaluation in various oncology indications as part of AqT's platform for advanced drug delivery.
- Other names
- STING agonist ADC payloadAqT Therapeutics STING agonist
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on AqT STING agonist payload.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AqT STING agonist payload.